Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 5,517 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Parkinson Disease
Interventions: Isradipine CR 5mg, Isradipine CR 10mg, Isradipine CR 20mg, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 18
States / cities: Sunnyvale, California • New Haven, Connecticut • Jacksonville, Florida + 14 more

Conditions: Anorexia, Cachexia, Weight Loss
Interventions: Megestrol acetate concentrated suspension 110 mg/mL, Placebo; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 3
States / cities: Miami, Florida • Cumberland, Maryland • Mt. Pleasant, South Carolina

Conditions: Uncontrolled Hypertension, Chronic Kidney Diseases
Interventions: CIN-107, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 71
States / cities: Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 65 more

Conditions: Obesity, Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 23
States / cities: Birmingham, Alabama • Montgomery, Alabama • Concord, California + 19 more

Conditions: Vitamin D Deficiency, Preterm Infants, Bronchopulmonary Dysplasia
Interventions: Cholecalciferol, Placebo; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Minute to 7 Days
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 22
States / cities: Long Beach, California • Sacramento, California • San Diego, California + 19 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more

Conditions: Insomia Disorder
Interventions: Daridorexant, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Little Rock, Arkansas • Lemon Grove, California • Pomona, California + 6 more

Conditions: Alzheimer's Disease
Interventions: Piromelatine, Placebo; Drug
Lead sponsor: Neurim Pharmaceuticals Ltd.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 56
States / cities: Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 47 more

Conditions: COVID-19
Interventions: Remdesivir, RDV Placebo, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more

Conditions: Diabetic Retinopathy, HIV
Interventions: Tesamorelin, Placebo-Control; Drug
Lead sponsor: Theratechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 24
States / cities: Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 17 more

Conditions: Lesch-Nyhan Disease, Self-injurious Behavior
Interventions: Ecopipam, Placebo; Drug
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 6 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteer
Interventions: Brensocatib, Moxifloxacin, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Neutropenia
Interventions: Mavorixafor, Placebo; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more

Conditions: Coronavirus, Covid19
Interventions: bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,044 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 207
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 12,537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetic Neuropathy
Interventions: Placebo, E2007 (2 mg), E2007 (4 mg), E2007 (6 mg), E2007 (8 mg); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus
Interventions: TAK-379, Pioglitazone, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Artesia, California • Norwalk, California • Santa Ana, California + 5 more

Conditions: Tobacco Dependence
Interventions: Varenicline, Nicotine patch, Placebo Patch, Placebo Pill; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1,251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: HCC
Interventions: Sorafenib, VT-122 (propranolol plus etodolac), Placebo; Drug
Lead sponsor: Vicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 10
States / cities: Berkeley, California • Atlanta, Georgia • New Brunswick, New Jersey + 6 more

Conditions: Breast Cancer
Interventions: Melatonin 3 mg; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Type2diabetes, Heart Failure With Reduced Ejection Fraction
Interventions: Empagliflozin 25 MG Oral Tablet, Placebo, Acipimox 250 Mg Oral Capsule; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Graft Versus Host Disease
Interventions: Belumosudil, Placebo, Prednisone, Prednisolone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 24
States / cities: Little Rock, Arkansas • Duarte, California • San Francisco, California + 21 more

Conditions: Restless Legs Syndrome
Interventions: XP13512, Diphenhydramine, Placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease

Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Vitamin D Supplementation for Extremely Preterm Infants

Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

ACTIV-2: A Study for Outpatients With COVID-19

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

UW Quitting Using Intensive Treatment Study (QUITS)

Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

Melatonin Versus Placebo in Breast Cancer

Ketones, SGLT2, HFrEF

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

Simulated Driving Study in Restless Legs Syndrome